BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst (Nasdaq: BCRX) announced on October 3, 2025 that its compensation committee granted inducement equity awards to eight newly hired employees.
The package includes 115,000 stock options and 91,450 restricted stock units (RSUs), granted effective October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). Options carry an exercise price of $7.37 (closing price on the grant date), vest in four equal annual installments beginning one year after grant, and have a 10-year term. Awards are subject to the company’s Inducement Equity Incentive Plan and applicable award agreements.
BioCryst (Nasdaq: BCRX) ha annunciato il 3 ottobre 2025 che il suo comitato per la retribuzione ha concesso premi azionari di induzione a otto dipendenti recentemente assunti.
Il pacchetto include 115.000 opzioni su azioni e 91.450 unità di azioni vincolate (RSU), concesse effettive a 1 ottobre 2025 ai sensi della Nasdaq Listing Rule 5635(c)(4). Le opzioni hanno un prezzo di esercizio di $7,37 (prezzo di chiusura nel giorno di conferimento), maturano in quattro rate annuali uguali a partire da un anno dopo la concessione, e hanno una durata di 10 anni. Le assegnazioni sono soggette al piano Inducement Equity Incentive della società e agli accordi di assegnazione applicabili.
BioCryst (Nasdaq: BCRX) anunció el 3 de octubre de 2025 que su comité de compensación otorgó premios de incentivo en acciones a ocho empleados recientemente contratados.
El paquete incluye 115,000 opciones sobre acciones y 91,450 unidades de acciones restringidas (RSU), otorgadas con efecto a partir del 1 de octubre de 2025 conforme a la Regla de Listado Nasdaq 5635(c)(4). Las opciones tienen un precio de ejercicio de $7.37 (precio de cierre en la fecha de otorgamiento), vencen en cuatro cuotas anuales iguales a partir de un año después de la concesión y tienen un plazo de 10 años. Los premios están sujetos al Plan de Incentivo de Equidad por Inducción de la empresa y a los acuerdos de adjudicación aplicables.
BioCryst (나스닥: BCRX)는 2025년 10월 3일에 보상의 위원회가 신규 채용된 여덟 명의 직원에게 유인 인센티브 주식 수여를 부여했다고 발표했습니다.
패키지에는 115,000주식 옵션과 91,450주식 제한 주식단위(RSU)가 포함되며, 2025년 10월 1일을 발효일로 하여 Nasdaq 상장 규칙 5635(c)(4)에 따라 부여되었습니다. 옵션의 행사가격은 $7.37이며(수여일 종가), 수여일로부터 1년 뒤부터 매년 1/4씩의 등가로 취득하고 유효기간 10년입니다. 수여는 회사의 Inducement Equity Incentive Plan 및 적용 가능한 수상 계약의 적용을 받습니다.
BioCryst (Nasdaq : BCRX) a annoncé le 3 octobre 2025 que son comité de rémunération a accordé des primes d’action incitatives à huit nouveaux employés.
Le paquet comprend 115 000 options d’achat et 91 450 unités d’actions restreintes (RSU), attribuées à effet le 1er octobre 2025 en vertu de la règle Nasdaq Listing 5635(c)(4). Les options ont un prix d’exercice de 7,37 $ (prix de clôture à la date d’octroi), se vestent en quatre versements annuels égaux à partir d’un an après l’octroi, et ont une durée de 10 ans. Les awards sont soumis au Plan d’intéressement en actions Inducement Equity Incentive de la société et aux accords d’attribution applicables.
BioCryst (Nasdaq: BCRX) kündigte am 3. Oktober 2025 an, dass sein Vergütungsausschuss Induzierungs-Aktienzuwendungen an acht neu eingestellte Mitarbeiter gewährt hat.
Das Paket umfasst 115.000 Aktienoptionen und 91.450 Restricted Stock Units (RSUs), mit Wirkung zum 1. Oktober 2025 gemäß Nasdaq Listing Rule 5635(c)(4). Optionen haben einen Ausübungspreis von 7,37 $ (Schlusskurs am Zuschreibungstag), vesten in vier gleichen jährlichen Raten ab dem ersten Jahr nach der Zuteilung und haben eine Laufzeit von 10 Jahren. Die Zuwendungen unterliegen dem Inducement Equity Incentive Plan des Unternehmens und den entsprechenden Award-Vereinbarungen.
BioCryst (ناسداك: BCRX) أعلنت في 3 أكتوبر 2025 أن لجنة التعويض لديها منحت جوائز أسهم تحفيزية لثمانية موظفين جدد تم تعيينهم.
تشمل الحزمة 115,000 خيار أسهم و 91,450 وحدة أسهم مقيدة (RSUs)، ممنوحة سرياً اعتباراً من 1 أكتوبر 2025 بموجب قاعدة إدراج ناسداك 5635(c)(4). تحمل الخيارات سعر ممارسة قدره 7.37 دولار (سعر الإغلاق في يوم المنح)، وتستحق على أربع دفعات سنوية متساوية تبدأ بعد عام واحد من المنح، ومدة 10 سنوات. تخضع الجوائز لخطة الحوافز بالأسهم Inducement Equity Incentive Plan وشروط الاتفاقات المعنية بالجوائز.
BioCryst (纳斯达克：BCRX) 宣布于 2025年10月3日，其薪酬委员会向八名新聘员工授予诱导性股票奖励。
该套餐包括 115,000份股票期权 和 91,450份受限股票单位（RSU），自 2025年10月1日起生效，依据纳斯达克上市规则5635(c)(4)授予。期权的行权价为 $7.37（授予日收盘价），自授予日起一年后开始分四年等额归属，期限为 10年。奖励受公司 Inducement Equity Incentive Plan 及相关奖项协议的约束。
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and restricted stock units (RSUs) covering an aggregate of 91,450 shares, of BioCryst common stock. The options and RSUs were granted as of October 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
What inducement awards did BioCryst (BCRX) grant on October 1, 2025?
What is the exercise price of the BCRX options granted as inducements?
When do the inducement options and RSUs for BCRX vest and expire?
Under which Nasdaq rule were the BioCryst inducement awards approved?
How many employees received inducement awards from BioCryst (BCRX)?
Are the BCRX inducement awards subject to plan terms or agreements?
